Insider Trading Alert - NHC, BIOL And ASGN Traded By Insiders

Stocks with insider trader activity include NHC, BIOL and ASGN
By TheStreet Wire ,

Yesterday, Nov. 12, 2015, 171 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $57.69 to $70,050,500.00.

Highlighted Stocks Traded by Insiders:

National Healthcare (NHC) - FREE Research Report

Flatt Stephen Fowler, who is President at National Healthcare, sold 2,300 shares at $66.20 on Nov. 12, 2015. Following this transaction, the President owned 44,983 shares meaning that the stake was reduced by 4.86% with the 2,300-share transaction.

The shares most recently traded at $65.12, down $1.08, or 1.66% since the insider transaction. Historical insider transactions for National Healthcare go as follows:

  • 4-Week # shares sold: 2,000
  • 12-Week # shares sold: 2,000
  • 24-Week # shares sold: 4,000

The average volume for National Healthcare has been 19,700 shares per day over the past 30 days. National Healthcare has a market cap of $974.4 million and is part of the health care sector and health services industry. Shares are up 3.91% year-to-date as of the close of trading on Thursday.

National HealthCare Corporation operates, manages, or provides services to skilled nursing facilities and associated assisted living centers, retirement centers, and home health care programs. The stock currently has a dividend yield of 2.45%. The company has a P/E ratio of 21.1. Currently, there are no analysts who rate National Healthcare a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NHC - FREE

TheStreet Quant Ratings

rates National Healthcare as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations and solid stock price performance. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full

National Healthcare Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Biolase (BIOL) - FREE Research Report

Lord Jonathan T Md, who is Director at Biolase, bought 16,310 shares at $0.75 on Nov. 12, 2015. Following this transaction, the Director owned 126,690 shares meaning that the stake was boosted by 14.78% with the 16,310-share transaction.

Dreyer David C, who is SVP / Chief Financial Officer at Biolase, bought 33,000 shares at $0.77 on Nov. 12, 2015. Following this transaction, the SVP / Chief Financial Officer owned 53,000 shares meaning that the stake was boosted by 165% with the 33,000-share transaction.

Flynn Harold C Jr., who is President and CEO at Biolase, bought 50,000 shares at $0.77 on Nov. 12, 2015. Following this transaction, the President and CEO owned 50,000 shares meaning that the stake was boosted by 100% with the 50,000-share transaction.

The shares most recently traded at $1.05, up $0.28, or 26.26% since the insider transaction. Historical insider transactions for Biolase go as follows:

  • 4-Week # shares bought: 5,000
  • 12-Week # shares bought: 20,000
  • 24-Week # shares bought: 20,000

The average volume for Biolase has been 150,300 shares per day over the past 30 days. Biolase has a market cap of $46.6 million and is part of the health care sector and health services industry. Shares are down 69.58% year-to-date as of the close of trading on Thursday.

BIOLASE, Inc., a medical device company, develops, manufactures, and markets laser systems in dentistry and medicine in the Unites States and internationally. Currently, there are no analysts who rate Biolase a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BIOL - FREE

TheStreet Quant Ratings

rates Biolase as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, poor profit margins, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full

Biolase Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

On Assignment (ASGN) - FREE Research Report

Sheridan Edwin A., who is Director at On Assignment, sold 64,402 shares at $45.93 on Nov. 12, 2015. Following this transaction, the Director owned 1.4 million shares meaning that the stake was reduced by 4.28% with the 64,402-share transaction.

The shares most recently traded at $45.51, down $0.42, or 0.93% since the insider transaction. Historical insider transactions for On Assignment go as follows:

  • 4-Week # shares sold: 133,000
  • 12-Week # shares bought: 1,006
  • 12-Week # shares sold: 133,000
  • 24-Week # shares bought: 1,006
  • 24-Week # shares sold: 532,000

The average volume for On Assignment has been 358,100 shares per day over the past 30 days. On Assignment has a market cap of $2.4 billion and is part of the services sector and diversified services industry. Shares are up 35.7% year-to-date as of the close of trading on Thursday.

On Assignment, Inc. provides short- and long-term placement of contract, contract-to-hire, and direct hire professionals in the United States, Europe, Canada, Australia, and New Zealand. The company operates in four segments: Apex, Oxford, Physician, and Life Sciences Europe. The company has a P/E ratio of 31.3. Currently, there are 7 analysts who rate On Assignment a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ASGN - FREE

TheStreet Quant Ratings

rates On Assignment as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, growth in earnings per share and increase in net income. We feel its strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full

On Assignment Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Loading ...